111 results on '"Mittler, Robert S."'
Search Results
102. Corrigendum: Long-lived antigen-induced IgM plasma cells demonstrate somatic mutations and contribute to long-term protection.
- Author
-
Bohannon, Caitlin, Powers, Ryan, Satyabhama, Lakshmipriyadarshini, Cui, Ang, Tipton, Christopher, Michaeli, Miri, Skountzou, Ioanna, Mittler, Robert S., Kleinstein, Steven H., Mehr, Ramit, Lee, Frances Eun-Hyung, Sanz, Ignacio, and Jacob, Joshy
- Published
- 2016
- Full Text
- View/download PDF
103. THE EXPRESSSION AND FUNCTION OF THE 41BB IN ALLOIMMUNE RESPONSES.
- Author
-
Tan, Joyce T., Ha, Jongwon, TuckerBurden, Carol, Hendrix, Rose C., Cho, Hong Rae, Mittler, Robert S., Pearson, Thomas C., and Larsen, Christian P.
- Published
- 2000
104. The B10 Idd9.3 Locus Mediates Accumulation of Functionally Superior CD137+ Regulatory T Cells in the Nonobese Diabetic Type 1 Diabetes Model.
- Author
-
Kachapati, Kritika, Adams, David E., Yuehong Wu, Steward, Charles A., Rainbow, Daniel B., Wicker, Linda S., Mittler, Robert S., and Ridgway, William M.
- Subjects
- *
T cells , *DIABETES prevention , *PANCREATIC beta cells , *SINGLE nucleotide polymorphisms , *ALLELES , *CELL proliferation - Abstract
CD137 is a T cell costimulatory molecule encoded by the prime candidate gene (designated Tnfrsf9) in NOD.B10 Idd9.3 congenic mice protected from type 1 diabetes (T1D). NOD T cells show decreased CD137-mediated T cell signaling compared with NOD. B10 Idd9.3 T cells, but it has been unclear how this decreased CD137+ T cell signaling could mediate susceptibility to T1D. We and others have shown that a subset of regulatory T cells (Tregs) constitutively expresses CD137+ (whereas effector T cells do not, and only express CD137+ briefly after activation). In this study, we show that the BiD Idd9.3 region intrinsically contributes to accumulation of CD137+ Tregs with age. NOD.B10 Idd9.3 mice showed significantly increased percentages and numbers of CD137+ peripheral Tregs compared with NOD mice. Moreover, Tregs expressing the B10 Idd9.3 region preferentially accumulated in mixed bone marrow chimeric mice reconstituted with allotypically marked NOD and NOD.B10 Idd9.3 bone marrow. We demonstrate a possible significance of increased numbers of CD137+ Tregs by showing functional superiority of FACS-purified CD137+ Tregs in vitro compared with CD137- Tregs in T cell-suppression assays. Increased functional suppression was also associated with increased production of the alternatively spliced CD137 isoform, soluble CD137, which has been shown to suppress T cell proliferation. We show for the first time, to our knowledge, that CD137+ Tregs are the primary cellular source of soluble CD137. NOD.B10 Idd9.3 mice showed significantly increased serum soluble CD137 compared with NOD mice with age, consistent with their increased numbers of CD137+ Tregs with age. These studies demonstrate the importance of CD137+ Tregs in T1D and offer a new hypothesis for how the NOD Idd9.3 region could act to increase T1D susceptibility. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
105. Host CD25+CD4+Foxp3+ Regulatory T Cells Primed by anti-CD137 mAbs Inhibit Graft-versus-Host Disease
- Author
-
Kim, Juyang, Kim, Wongyoung, Kim, Hyun J., Park, Sohye, Kim, Hyun-A., Jung, Daehee, Choi, Hye-Jung, Park, Sang J., Mittler, Robert S., Cho, Hong R., and Kwon, Byungsuk
- Subjects
- *
GRAFT versus host disease , *CELL proliferation , *IMMUNOSUPPRESSIVE agents , *LABORATORY mice , *SPLEEN diseases , *HEMATOPOIETIC stem cells - Abstract
CD25+CD4+Foxp3+ regulatory T cells (Tregs) play a pivotal role in the maintenance of self-tolerance and regulation of immune responses. Previous studies have demonstrated that CD137 signals can promote proliferation and survival of Tregs in vitro. Here, we show that in vivo CD137-induced expansion of Tregs in naive mice was dependent upon IL-2 secreted by memory T cells. Tregs primed by anti-CD137 mAbs had a higher immunosuppressive capacity. Preconditioning with anti-CD137 mAbs significantly inhibited graft-versus-host disease (GVHD) in the C57BL/6 → (C57BL/6 × DBA/2) F1 acute GVHD model. In this disease model, a high proportion of host Tregs remained long-term in the recipient spleen, whereas donor hematopoietic cells replaced other host bone marrow-derived cells. Transient depletion of Tregs before transfer of donor cells completely abrogated the inhibitory effect of anti-CD137 mAbs on GVHD. In addition, adoptive transfer of anti-CD137-primed Tregs ameliorated GVHD. Our results demonstrate that it is possible to enhance the survival and/or the immunosuppressive activity of host Tregs in nonmyeloablative GVHD, and that 1 way of accomplishing this is through the prophylactic use of anti-CD137 mAbs in nonmyeloablative GVHD. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
106. Immune suppression or enhancement by CD137 T cell costimulation during acute viral infection is time dependent.
- Author
-
Benyue Zhang, Maris, Charles H., Foell, Juergen, Whitmire, Jason, Liguo Niu, Jing Song, Kwon, Byoung S., Vella, Anthony T., Ahmed, Rafi, Jacob, Joshy, and Mittler, Robert S.
- Subjects
- *
IMMUNE response , *IMMUNOSUPPRESSION , *IMMUNOREGULATION , *IMMUNOLOGICAL tolerance , *LYMPHOCYTIC choriomeningitis virus , *RESPIRATORY infections - Abstract
CD137 is expressed on activated T cells and ligands to this costimulatory molecule have clinical potential for amplifying CD8 T cell immunity to tumors and viruses, while suppressing CD4 autoimmune T cell responses. To understand the basis for this dichotomy in T cell function, CD4 and CD8 antiviral immunity was measured in lymphocytic choriomeningitis virus (LCMV) Armstrong- or A/PR8/34 influenza-infected mice injected with anti-CD137 mAbs. We found that the timing of administration of anti-CD137 mAbs profoundly altered the nature of the antiviral immune response during acute infection. Antiviral immunity progressed normally for the first 72 hours when the mAb was administered early in infection before undergoing complete collapse by day 8 postinfection. Anti-CD137-injected LCMV-infected mice became tolerant to, and persistently infected with, LCMV Armstrong. Elevated levels of IL-10 early in the response was key to the loss of CD4+ T cells, whereas CD8+ T cell deletion was dependent on a prolonged TNF-α response, IL-10, and upregulation of Fas. Blocking IL-10 function rescued CD4 antiviral immunity but not CD8+ T cell deletion. Anti-CD137 treatment given beyond 72 hours after infection significantly enhanced antiviral immunity. Mice treated with anti-CD137 mAb 1 day before infection with A/PR8/34 virus experienced 80% mortality compared with 40% mortality of controls. When treatment was delayed until day 1 postinfection, 100% of the infected mice survived. These data show that anti-CD137 mAbs can induce T cell activation-induced cell death or enhance antiviral immunity depending on the timing of treatment, which may be important for vaccine development. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
107. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F[sub1] mice.
- Author
-
Foell, Juergen, Strahotin, Simona, O'Neil, Shawn P., McCausland, Megan M., Suwyn, Carolyn, Haber, Michael, Chander, Praveen N., Bapat, Abhijit S., Xiao-Jie Yah, Chiorazzi, Nicholas, Hoffmann, Michael K., and Mittler, Robert S.
- Subjects
- *
LUPUS erythematosus , *AUTOIMMUNE diseases , *T cells , *IMMUNOGLOBULINS , *PREGNANT women , *AUTOANTIBODIES - Abstract
Systemic lupus erythematosus (SLE) is a CD4[sup+] T cell-dependent, immune complex-mediated, autoimmune disease that primarily affects women of childbearing age. Generation of high-titer affinity-matured IgG autoantibodies, specific for double-stranded DNA and other nuclear antigens, coincides with disease progression. Current forms of treatment of SLE including glucocorticosteroids are often inadequate and induce severe side effects. Immunological approaches for treating SLE in mice using anti-CD4 mAb's or CTLA4-Ig and anti-CD 154 mAb's have proven to be effective. However, like steroid treatment, these regimens induce global immunosuppression, and their withdrawal allows for disease progression. In this report we show that lupus-prone NZB x NZW F[sub1] mice given three injections of anti-CD137 (4-1BB) mAb's between 26 and 35 weeks of age reversed acute disease, blocked chronic disease, and extended the mice's lifespan from 10 months to more than 2 years. Autoantibody production in recipients was rapidly suppressed without inducing immunosuppression. Successful treatment could be traced to the fact that NZB x NZW F[sub1] mice, regardless of their age or disease status, could not maintain pathogenic IgG autoantibody production in the absence of continuous CD4[sup+] T cell help. Our data support the hypothesis that CD 137-mediated signaling anergized CD4[sup+] T cells during priming at the DC interface. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
108. Antigen-specific CD4+ T cells recognize epitopes of protective antigen following vaccination with an anthrax vaccine.
- Author
-
Laughlin EM, Miller JD, James E, Fillos D, Ibegbu CC, Mittler RS, Akondy R, Kwok W, Ahmed R, and Nepom G
- Subjects
- Cell Proliferation, Cytokines biosynthesis, Flow Cytometry, Humans, Lymphocyte Activation, Lymphocyte Subsets immunology, Th1 Cells immunology, Th2 Cells immunology, Anthrax Vaccines immunology, Antigens, Bacterial immunology, Bacillus anthracis immunology, Bacterial Toxins immunology, CD4-Positive T-Lymphocytes immunology, Epitopes immunology
- Abstract
Detection of antigen-specific CD4+ T cells is facilitated by the use of fluorescently labeled soluble peptide-major histocompatibility complex (MHC) multimers which mirror the antigen specificity of T-cell receptor recognition. We have used soluble peptide-MHC class II tetramers containing peptides from the protective antigen (PA) of Bacillus anthracis to detect circulating T cells in peripheral blood of subjects vaccinated with an anthrax vaccine. PA-specific HLA class II-restricted T lymphocytes were isolated which displayed both TH1- and TH2-like characteristics, indicating heterogeneity of the lymphocyte lineage within the CD4+ response. Presentation of antigen to these T-cell clones by HLA-matched antigen-presenting cells exposed to the intact PA protein confirmed that the identified epitopes are indeed naturally processed by the human immune system. Specific tetramer-derived T-cell profiling may be useful for monitoring helper CD4+ T-cell responses to anthrax vaccination.
- Published
- 2007
- Full Text
- View/download PDF
109. T cell costimulatory and inhibitory receptors as therapeutic targets for inducing anti-tumor immunity.
- Author
-
Foell J, Hewes B, and Mittler RS
- Subjects
- Animals, Antigen-Presenting Cells physiology, Antigens, CD physiology, Antigens, Differentiation physiology, B7-2 Antigen physiology, B7-H1 Antigen, CTLA-4 Antigen, Humans, Intercellular Signaling Peptides and Proteins physiology, OX40 Ligand physiology, Programmed Cell Death 1 Ligand 2 Protein, Signal Transduction, Tumor Necrosis Factor Receptor Superfamily, Member 9 physiology, B7-1 Antigen physiology, CD28 Antigens physiology, Lymphocyte Activation, Neoplasms immunology, T-Lymphocytes immunology
- Abstract
Central to the normal function of the immune system is its ability to distinguish between self and non-self since failure to do so could provoke the onset of autoimmune disease. To avoid this possibility, the immune system employs several processes that include, negative selection, peripheral tolerance, and limiting DC antigen priming of naïve T cells to the lymph nodes. Naïve T cells must receive two independent signals from these antigen-presenting cells (APC) that other cells cannot provide if they are to become productively activated. The first is antigen-specific and occurs when T cell antigen receptors encounter the appropriate antigen-MHC complex on the APC--Signal 1. A second, antigen-independent signal is delivered through a T cell costimulatory molecule that engages its APC-expressed ligands--Signal 2. In the absence of a costimulatory signal T cells typically enter a state of anergy. Furthermore, the extent to which T cell activation occurs can be held in check through specific inhibitory receptors expressed on T cells. Understanding the basic mechanisms of how T cell activation is regulated has led to the development of therapeutic approaches for targeting T cell costimulatory and inhibitory pathways for turning on, or preventing the turning off immune responses in subjects with cancer. In this review we will discuss several T cell costimulatory and inhibitory pathways known to influence the development of anti-tumor immunity and how experimental manipulation of these signaling pathways has led to the generation of protective, or curative anti-tumor immunity in mice and humans.
- Published
- 2007
- Full Text
- View/download PDF
110. Peptide-specific CD8 T regulatory cells use IFN-gamma to elaborate TGF-beta-based suppression.
- Author
-
Myers L, Croft M, Kwon BS, Mittler RS, and Vella AT
- Subjects
- Animals, Antigens, CD biosynthesis, CD4-Positive T-Lymphocytes immunology, Cell Proliferation, Cells, Cultured, Egg Proteins administration & dosage, Epitopes, T-Lymphocyte administration & dosage, Integrin alpha Chains biosynthesis, Interferon-gamma metabolism, Ligands, Lymphocyte Activation immunology, Mice, Mice, Inbred C57BL, Mice, Knockout, Mice, Mutant Strains, Mice, Transgenic, Ovalbumin administration & dosage, Peptide Fragments, Protein Binding immunology, Receptors, Interferon metabolism, Receptors, Interferon physiology, Interferon gamma Receptor, Egg Proteins immunology, Epitopes, T-Lymphocyte immunology, Interferon-gamma physiology, Ovalbumin immunology, T-Lymphocytes, Regulatory immunology, T-Lymphocytes, Regulatory metabolism, Transforming Growth Factor beta physiology
- Abstract
We identified a murine peptide-specific CD8 T regulatory cell population able to suppress responding CD4 T cells. Immunization with OVA, poly(I:C), and anti-4-1BB generated a population of SIINFEKL-specific CD8 T regulatory cells that profoundly inhibited peptide-responding CD4 T cells from cellular division. The mechanism of suppression required IFN-gamma, but IFN-gamma alone was not sufficient to suppress the responding CD4 T cells. The data show that CD8 T regulatory cells were unable to suppress unless they engaged IFN-gamma. Furthermore, even in the absence of recall with peptide, the CD8 T regulatory cells suppressed CD4 responses as long as IFN-gamma was present. To examine the effector mechanism of suppression, we showed that neutralizing TGF-beta inhibited suppression because inclusion of anti-TGF-beta rescued the proliferative capacity of the responding cells. TGF-beta-based suppression was dependent completely upon the CD8 T regulatory cells being capable of binding IFN-gamma. This was the case, although peptide recall of primed IFN-gamma (-/-) or IFN-gammaR(-/-) CD8 T cells up-regulated pro-TGF-beta protein as measured by surface latency-associated peptide expression but yet were unable to suppress. Finally, we asked whether the CD8 T regulatory cells were exposed to active TGF-beta in vivo and showed that only wild-type CD8 T regulatory cells expressed the TGF-beta-dependent biomarker CD103, suggesting that latency-associated peptide expression is not always congruent with elaboration of active TGF-beta. These data define a novel mechanism whereby IFN-gamma directly stimulates CD8 T regulatory cells to elaborate TGF-beta-based suppression. Ultimately, this mechanism may permit regulation of pathogenic Th1 responses by CD8 T regulatory cells.
- Published
- 2005
- Full Text
- View/download PDF
111. Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering.
- Author
-
Myers L, Takahashi C, Mittler RS, Rossi RJ, and Vella AT
- Subjects
- Animals, Antigens, CD, Flow Cytometry, Mice, Toll-Like Receptor 3, Toll-Like Receptor 4, Toll-Like Receptors, Tumor Necrosis Factor Receptor Superfamily, Member 9, CD8-Positive T-Lymphocytes immunology, Drosophila Proteins, Membrane Glycoproteins immunology, Receptors, Cell Surface immunology, Receptors, Nerve Growth Factor immunology, Receptors, Tumor Necrosis Factor immunology
- Abstract
To better understand how innate and adaptive immune responses interact with each other, we combined 4-1BB T cell costimulation with specific adjuvants to determine whether these treatments would influence specific T cell expansion and function in vivo. In the presence of 4-1BB ligation and Toll-like receptor 3 (TLR)3 and/or TLR4 triggering, CD8 T cell clonal expansion and survival was augmented profoundly. Specific T cells primed in vivo with TLR ligands responded normally to in vitro recall stimulus, but, surprisingly, copriming with 4-1BB costimulation significantly impaired the recall response even though many more specific effector T cells were rescued in vivo. Here, we demonstrate that the rescued CD8 T cells suppressed CD4 T cell proliferation via a type beta transforming growth factor-dependent mechanism. Thus, 4-1BB and TLR ligands induce survival of specific effector CD8 T cells with suppressive recall potential, which may explain the dual role that 4-1BB activation plays in mediating tumor clearance and prevention of autoimmune disease.
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.